NEWS

WIRES

OTHER

Hana Biosciences to Present Data On Marqibo, Its Lead Novel Anti-Cancer Compound, At 2008 American Society of Hematology (ASH) Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 1, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences , a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that several presentations related to the Company's lead anti-cancer compound, Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)), will be presented at the upcoming annual meeting of the American Society of Hematology (ASH) in San Francisco during December 6-9, 2008.

The following posters will be presented in Hall A of the Moscone Center at the ASH annual meeting. Text of these abstracts can be viewed on the ASH website at www.hematology.org.

 * In Vivo Anti-Tumor Efficacy of Vincristine Sulfate Liposomes
   Injection (VSLI, Marqibo) in Multiple Myeloma   

 * Peripheral Neuropathy Profile of Vincristine Sulfate Liposomes
   Injection (VSLI, Marqibo), a Nanoparticle Vincristine Formulation,
   in Adult Subjects with Relapsed/Refractory Acute Lymphoblastic
   Leukemia (ALL) and Non-Hodgkin's Lymphoma (NHL)  

 * Phase 1 Study of Weekly Vincristine Sulfate (VCR) Liposomes
   Injection (VSLI, Marqibo) Plus Dexamethasone in Adults with Relapsed
   or Refractory Acute Lymphoblastic Leukemia (ALL) 

About Hana Biosciences, Inc.

Hana Biosciences, Inc. is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to strengthen the foundation of cancer care. The company is committed to creating value by building a best-in-class team, accelerating the development of lead product candidates, expanding its pipeline by being an alliance partner of choice, and nurturing a unique company culture. Further information on Hana Biosciences can be found at www.hanabiosciences.com.

The Hana Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3290

CONTACT:  Hana Biosciences
          Investor & Media Contacts:
          Investor Relations Team
          (650) 588-6641
          investor.relations@hanabiosciences.com

          Invigorate Communications
          Gregory Gin
          (908) 376-7737
          ggin@invigoratepr.com